RAD April 2022 Conference Abstracts and Posters
183 - Use of Systemic Therapy in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis from the CorEvitas Atopic Dermatitis Registry
Eric L. Simpson MD, MCR, Eric A. Jones PhD, MPH, Angel Cronin MS, Swapna S Dave MPH, MBBS, Robert R. McLean DSc, MPH, Jeffrey Greenberg MD, MPH, Bruce Strober MD, PhD, Thomas Bieber MD, PhD, Melinda Gooderham MSc, MD, FRCPC, Amy S. Paller MD, Jonathan I. Silverberg MD, PhD, MPH
184 - Real-world Psychosocial and Economic Burden of Atopic Dermatitis Related to Disease Severity and Use of Systemic Therapy: Results from a Multicountry Study
Valeria Aoki, Kilian Eyerich, Peter Schmid-Grendelmeier, Spyridon Gkalpakiotis, Henrique D. Teixeira, Shunya Takemoto, Brian M. Calimlim, Shirley H. Chen, Cristina Sancho, Juan Francisco Silvestre
185 - Real-World Achievement of Atopic Dermatitis Treat-to-Target Disease Domain Criteria: Results From a Multicountry Study
Marjolein S. de Bruin-Weller, Felix Lauffer, Roberta F. J. Criado, Daciana E. Branisteanu, Henrique D. Teixeira, Shunya Takemoto, Brian M. Calimlim, Shirley H. Chen, Cristina Sancho, Jonathan I. Silverberg
186 - Longitudinal course and predictors of depressive symptoms in atopic dermatitis
Sheena Chatrath, BA; Donald Lei, MS; Muhammad Yousaf, BS; Rajeev Chavda, MD; Sylvie Gabriel, MD; Jonathan Silverberg, MD, PhD, MPH
188 - Racial and ethnic differences in sociodemographic and treatment characteristics among patients with atopic dermatitis in the United States: Real-world data from CorEvitas registry
Jonathan I. Silverberg, MD, PhD, MPH; Vivian Y. Shi, MD; Andrew Alexis, MD, MPH; Evangeline Pierce, PhD; Angel Cronin, MS; Robert R. McLean, DSc, MPH; Carla Roberts-Toler, MSc; Maria Jose Rueda, MD; Amber R. Atwater, MD; Eric Simpson, MD, MCR
189 - The burden of atopic dermatitis polypharmacy and out-of-pocket healthcare expenses in the United States
Raj Chovatiya, MD, PhD, Wendy Smith Begolka, MBS, Isabelle J. Thibau, MPH, Jonathan I. Silverberg, MD, PhD, MPH
190 - Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson
194 - Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks
Weily Soong, Andrew Blauvelt, Andreas Wollenberg, H. Chih-ho Hong, Jeffrey Leflein, Anthony Bewley, Petra Amoudruz, Marie Holst Moerch, Lise Soldbro, Shannon Schneider, Eric L. Simpson, Amy Paller
195 -Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
Andrew Blauvelt, Richard Langley, Eric Simpson, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Stine Fangel, Nathan Lassota, Anna Carlsson, Darryl Toth, Marie Tauber, Andreas Pinter, Mahreen Ameen, Kristian Reich
196 - Prevalence, predictors and longitudinal course of sexual dysfunction in adults with atopic dermatitis
Trisha Kaundinya BS; Uros Rakita MSc; Jonathan I. Silverberg MD, PhD, MPH